Class information for: |
Basic class information |
ID | Publications | Average number of references |
Avg. shr. active ref. in WoS |
---|---|---|---|
5224 | 1586 | 47.7 | 90% |
Classes in level above (level 2) |
ID, lev. above |
Publications | Label for level above |
---|---|---|
2970 | 2159 | ALPHAVBETA3 INTEGRIN//CILENGITIDE//DISCOIDIN DOMAIN RECEPTOR |
Terms with highest relevance score |
Rank | Term | Type of term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|---|
1 | ALPHAVBETA3 INTEGRIN | Author keyword | 74 | 42% | 9% | 137 |
2 | CILENGITIDE | Author keyword | 73 | 80% | 3% | 45 |
3 | ALPHAVBETA3 | Author keyword | 28 | 39% | 4% | 57 |
4 | MED ISOTOPES | Address | 24 | 44% | 3% | 40 |
5 | INTETUMUMAB | Author keyword | 21 | 90% | 1% | 9 |
6 | RGD | Author keyword | 13 | 14% | 6% | 89 |
7 | RGD PEPTIDES | Author keyword | 12 | 29% | 2% | 36 |
8 | F 18 GALACTO RGD | Author keyword | 11 | 100% | 0% | 6 |
9 | RGD PEPTIDE | Author keyword | 10 | 16% | 4% | 60 |
10 | ALPHAVBETA3 ANTAGONISTS | Author keyword | 8 | 100% | 0% | 5 |
Web of Science journal categories |
Author Key Words |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ALPHAVBETA3 INTEGRIN | 74 | 42% | 9% | 137 | Search ALPHAVBETA3+INTEGRIN | Search ALPHAVBETA3+INTEGRIN |
2 | CILENGITIDE | 73 | 80% | 3% | 45 | Search CILENGITIDE | Search CILENGITIDE |
3 | ALPHAVBETA3 | 28 | 39% | 4% | 57 | Search ALPHAVBETA3 | Search ALPHAVBETA3 |
4 | INTETUMUMAB | 21 | 90% | 1% | 9 | Search INTETUMUMAB | Search INTETUMUMAB |
5 | RGD | 13 | 14% | 6% | 89 | Search RGD | Search RGD |
6 | RGD PEPTIDES | 12 | 29% | 2% | 36 | Search RGD+PEPTIDES | Search RGD+PEPTIDES |
7 | F 18 GALACTO RGD | 11 | 100% | 0% | 6 | Search F+18+GALACTO+RGD | Search F+18+GALACTO+RGD |
8 | RGD PEPTIDE | 10 | 16% | 4% | 60 | Search RGD+PEPTIDE | Search RGD+PEPTIDE |
9 | ALPHAVBETA3 ANTAGONISTS | 8 | 100% | 0% | 5 | Search ALPHAVBETA3+ANTAGONISTS | Search ALPHAVBETA3+ANTAGONISTS |
10 | RGD DIMER | 8 | 100% | 0% | 5 | Search RGD+DIMER | Search RGD+DIMER |
Key Words Plus |
Rank | Web of Science journal category | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | ALPHAVBETA3 | 128 | 31% | 22% | 351 |
2 | ALPHAVBETA3 INTEGRIN | 79 | 21% | 21% | 336 |
3 | CANCER ALPHAV INTEGRIN EXPRESSION | 79 | 85% | 3% | 41 |
4 | INTEGRIN ALPHAVBETA3 EXPRESSION | 61 | 58% | 4% | 71 |
5 | F 18 GALACTO RGD | 47 | 88% | 1% | 22 |
6 | GLIOMA INTEGRIN ALPHAVBETA3 EXPRESSION | 44 | 88% | 1% | 21 |
7 | ALPHAVBETA3 ANTAGONISTS | 37 | 75% | 2% | 27 |
8 | ALPHA V BETA 3 EXPRESSION | 32 | 85% | 1% | 17 |
9 | VITRONECTIN RECEPTOR ANTAGONISTS | 32 | 85% | 1% | 17 |
10 | CILENGITIDE | 30 | 60% | 2% | 33 |
Journals |
Reviews |
Title | Publ. year | Cit. | Active references | % act. ref. to same field |
---|---|---|---|---|
Integrins in cancer: biological implications and therapeutic opportunities | 2010 | 811 | 187 | 44% |
RGD-Based Strategies To Target Alpha(v) Beta(3) Integrin in Cancer Therapy and Diagnosis | 2012 | 115 | 95 | 49% |
Ligands for Mapping alpha(v)beta(3)-Integrin Expression in Vivo | 2009 | 138 | 73 | 77% |
Radiolabeled Cyclic RGD Peptides as Integrin alpha(v)beta(3)-Targeted Radiotracers: Maximizing Binding Affinity via Bivalency | 2009 | 145 | 120 | 72% |
Radiolabelled RGD peptides for imaging and therapy | 2012 | 53 | 71 | 76% |
Integrins as therapeutic targets | 2012 | 87 | 57 | 47% |
Tumor angiogenesis: molecular pathways and therapeutic targets | 2011 | 337 | 141 | 16% |
Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance | 2015 | 4 | 57 | 12% |
Integrins in angiogenesis and lymphangiogenesis | 2008 | 358 | 139 | 34% |
Radiolabeled multimeric cyclic RGD peptides as integrin alpha(v)beta(3) targeted radiotracers for tumor imaging | 2006 | 175 | 84 | 71% |
Address terms |
Rank | Address term | Relevance score (tfidf) |
Class's shr. of term's tot. occurrences |
Shr. of publ. in class containing term |
Num. of publ. in class |
---|---|---|---|---|---|
1 | MED ISOTOPES | 24 | 44% | 2.5% | 40 |
2 | INTERDIPARTIMENTALE STUDI BIOMOL PLICAZ I | 8 | 100% | 0.3% | 5 |
3 | ONCOL PLATFORM | 6 | 100% | 0.3% | 4 |
4 | RADIOL MIPS | 6 | 100% | 0.3% | 4 |
5 | MOL IMAGING NANOMED | 5 | 18% | 1.5% | 24 |
6 | INTER PRECLIN DEV MOL IMAGING CISPIM | 4 | 67% | 0.3% | 4 |
7 | RADIOL BIOX | 4 | 67% | 0.3% | 4 |
8 | ADHES ANGIOGENESIS GRP | 4 | 75% | 0.2% | 3 |
9 | EUGENE MARCIA PELBAUM INVAS MOL THER E | 3 | 100% | 0.2% | 3 |
10 | BONE BIOL OSTEOPOROSIS | 3 | 19% | 0.9% | 15 |
Related classes at same level (level 1) |
Rank | Relatedness score | Related classes |
---|---|---|
1 | 0.0000169465 | DISINTEGRIN//DISINTEGRINS//ECHISTATIN |
2 | 0.0000114146 | LTBP//ALPHA V BETA 6//INTEGRIN ALPHAVBETA6 |
3 | 0.0000113728 | ALPHA 6 BETA 4 INTEGRIN//INTEGRIN ALPHA 6 BETA 4//CANC BIOL ANGIOGENESIS |
4 | 0.0000110232 | MULTIMERIC LIGANDS//NDP ALPHA MSH//DISSOCIATION ENHANCED LANTHANIDE FLUOROIMMUNOASSAY |
5 | 0.0000108115 | ISTHMIN//METEORIN//NEURENSIN 2 |
6 | 0.0000106898 | FLUORINE 18//F 18SFB//RADIOFLUORINATION |
7 | 0.0000074104 | NEAR INFRARED FLUORESCENCE IMAGING//NEAR INFRARED FLUORESCENCE//FLUORESCENT CHOLANGIOGRAPHY |
8 | 0.0000072714 | GE 68 GA 68 GENERATOR//GALLIUM 68//GA 68 |
9 | 0.0000063976 | LUNASIN//CHEMOPREVENTIVE PEPTIDE//CORE HISTONE ACETYLATION |
10 | 0.0000060698 | CDKN3//CYCLIN DEPENDENT KINASE ASSOCIATED PROTEIN PHOSPHATASE//CYTOKINE EXPRESSION PATTERN |